低剂量的氨酸准KCNH6,以增强葡萄糖诱导的胰岛素分泌
Feng-Ran Xiong1,2, Juan-Juan Zhu1,2, Xiao-Rong Zhu1,2
1Department of Endocrinology, Beijing Diabetes Institute, Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Journal of molecular cell biology
|January 23, 2025
概括
低剂量的氨酸通过抑制胰腺细胞中的KCNH6通道来增强葡萄糖诱导的胰岛素分泌,改善葡萄糖耐受性. 这种效果取决于KCNH6,而不是对ATP敏感的通道.
科学领域:
- 电子生理学 电子生理学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素分泌是由K+通道活动调节的,ATP敏感的K+ (KATP) 通道调节脱极化,K+外流通道调节再极化.
- 抗疟疾药物因因胰岛素释放而导致低血糖,可能通过KATP通道抑制.
- 在胰腺β细胞再极化中的KCNH6 (hERG2) 通道的作用以及因对它们的影响需要进一步研究.
研究的目的:
- 为了研究低剂量因在分离的小鼠胰腺小岛上的胰岛素特效.
- 为了确定因是否向KCNH6通道以增强葡萄糖诱导的胰岛素分泌.
- 阐明KCNH6在因中介改善葡萄糖耐受性和胰岛素释放中的作用.
主要方法:
- 补丁电生理学,以评估因对hERG通道的影响.
- 使用野生类型和Kcnh6-β细胞特异性淘汰 (βKO) 小鼠进行体内研究,以评估葡萄糖耐受性和胰岛素释放.
- 在实验室内对来自野生类型和βKO小鼠的初级岛屿β细胞进行研究,以测量Ca2+流入和作用潜力的持续时间.
主要成果:
- 低剂量 (<20μM) 强化了高葡萄糖诱导的胰岛素分泌和Ca2+涌入,但没有直接引起Ca2+峰值.
- 氨酸在低微分子度下抑制了hERG通道.
- 在体内和体外实验表明,因对葡萄糖耐受性和胰岛素分泌的影响在Kcnh6-βKO小鼠中被废除.
- 氨酸延长了作用潜力的持续时间和增加了葡萄糖诱导的Ca2+流入野生类型细胞,但不是βKO细胞.
结论:
- KCNH6通道对于低剂量氨酸强化胰岛素分泌至关重要.
- 氨酸提高葡萄糖耐受性和胰岛素释放的能力是通过KCNH6通道抑制进行介导的.
- 这些发现为KCNH6作为管理葡萄糖代谢的潜在药物开发目标提供了新的见解.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Glucose Absorption Into the Small Intestine
31.5K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.5K
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178


